Clinical trials: Nash
Non-alcoholic Fatty Liver Disease
Focused Power Ultrasound Mediated Inferior Perirenal Adipose Tissue Modification Therapy for Non-Alcoholic Fatty Liver Disease (PARADISE-NAFLD)
This randomized, blinded, sham-control trial aims to evaluate the efficacy and safety of a novel focused power ultrasound mediated inferior perirenal adipose tissue modification therapy for non-alcoholic fatty liver disease.
- Trial name
- NCT06225713
- Testing
- focused power ultrasound mediated inferior perirenal adipose tissue modification
- Where
- 3 sites in China
- Volunteers
- 80 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Healthy, NAFLD
DDI Study of ASC41 in HV and the PK, Safety and Tolerability in Subjects With NAFLD.
The primary objective of this study is to evaluate the effect of itraconazole, a strong inhibitor)of cytochrome P4503A , and phenytoin a strong inducer of cytochrome P450 3A, CYP3A4, CYP1A2 and CYP2C19 on the pharmacokinetics of…
- Trial name
- NCT04845646
- Testing
- ASC41, Itraconazole, Phenytoin
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Gannex Pharma Co., Ltd.
Type 2 Diabetes, NAFLD
Diabetes Nutrition Algorithms in Patients With Overt Diabetes Mellitus
Basic treatment of type 2 diabetes should focus on diet, physical activity and lifestyle. Nevertheless, in early and late stage of T2DM, lifestyle intervention is mostly substituted by pharmacological intervention, although…
- Conditions
- Type 2 Diabetes, NAFLD, Obesity, Dyslipoproteinaemia
- Trial name
- DiNA-D (NCT02459496)
- Testing
- dietary consulting and advise
- Where
- 2 sites in Germany
- Volunteers
- 200 people
- Sponsor
- German Institute of Human Nutrition
NASH - Nonalcoholic Steatohepatitis
Effect of DMR in the Treatment of NASH
Non-alcoholic fatty liver disease (NAFLD) is a frequent disease affecting up to 25% of the USA population, 2-44% in Europe and up to 42,6-69,5% in patients with type 2 diabetes.
- Trial name
- DMR_NASH_001 (NCT03536650)
- Testing
- DMR
- Where
- Belgium
- Volunteers
- 14 people
- Sponsor
- Erasme University Hospital
NAFLD, Heart Failure
T1-mapping by Cardiovascular Magnetic Resonance Imaging to Assess Non-Alcoholic Fatty Liver Disease
On clinically indicated Cardiovascular Magnetic Resonance studies, native T1-times and extracellular volume of the liver will be assessed and findings correlated with established risk calculators for non-alcoholic fatty liver…
- Conditions
- NAFLD, Heart Failure, Valvular Disease, Coronary Disease
- Trial name
- NCT04220450
- Testing
- T1 mapping on Cardiovascular Magnetic Resonance Studies
- Where
- Austria
- Volunteers
- 800 people
- Sponsor
- Dr. Andreas Kammerlander
NAFLD
An Investigator Initiated Prospective, Four Arms Randomized Comparative Study of Efficacy and Safety of Saroglitazar, Vitamin E and Life Style Modification in Patients With Nonalcoholic Fatty Liver Disease (NAFLD)/ Non-alcoholic Steatohepatitis (NASH)
Saroglitazar and Vitamin E are both being extensively used in India for non alcoholic fatty liver disease, though none of these drugs are FDA approved for this indication.However they are backed up by number of studies which…
- Trial name
- NCT04193982
- Testing
- Saroglitazar, Vitamin E, Combination drug
- Where
- India
- Volunteers
- 250 people
- Sponsor
- Asian Institute of Gastroenterology, India
Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis
This is a phase 2 randomized, double-blind, placebo-controlled parallel group study of 3 dose levels of HU6 in subjects with nonalcoholic steatohepatitis (NASH).
- Conditions
- Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Fatty Liver
- Trial name
- NCT05979779
- Testing
- HU6
- Where
- 20 sites in United States
- Volunteers
- 219 people
- Sponsor
- Rivus Pharmaceuticals, Inc.
Non-Alcoholic Fatty Liver Disease (NAFLD)
Proliverenol Supplementation for Non-Alcoholic Fatty Liver Disease (NAFLD)
This is a 4-arm, prospective, randomized, double-blind, double-dummy, and placebo-controlled clinical study comparing Proliverenol at a dose of 500 mg twice daily; Proliverenol at a dose of 1000 mg once daily; Proliverenol at a…
- Trial name
- NCT06127225
- Testing
- Proliverenol
- Where
- Indonesia
- Volunteers
- 80 people
- Sponsor
- Dexa Medica Group
Non-Alcoholic Fatty Liver Disease, Non Alcoholic Steatohepatitis
Effect of Patient Demographics, Comorbidities, and Medications on Severity of NASH Fibrosis
Few studies have evaluated an extensive list of possible risk factors for NAFLD for their association with presence and severity of histologic features.
- Trial name
- NCT05357352
- Testing
- NAFLD/NASH
- Where
- United States
- Volunteers
- 263 people
- Sponsor
- Methodist Health System
Nonalcoholic Fatty Liver Disease
Prospective Cohort, With Biobanking, of Patients With Nonalcoholic Fatty Liver Disease
The aim of the present prospective NAFLD cohort study (with biobank), of obese subjects with proven NAFLD based on liver biopsy and/or MRI, is to study factors contributing to the development of NASH in patients with simple…
- Trial name
- NAFLD-cohort (NCT02422238)
- Where
- Netherlands
- Volunteers
- 500 people
- Sponsor
- Maastricht University Medical Center
Non-Alcoholic Fatty Liver Disease, Hyperuricemia
Assocaiton Between Uric Acid Trajecteries and Remission of NAFLD in NAFLD Individuals
Uric acid is the end product of dietary or endogenous purines degradation, and hyperuricemia is one of the most common metabolic disorders.
- Trial name
- NCT05245890
- Volunteers
- 2,000 people
- Sponsor
- Ningbo No. 1 Hospital
Non-alcoholic Fatty Liver Disease, Obesity
A Study to Test How Well Different Doses of BI 3006337 Are Tolerated by People With Overweight or Obesity and With Fatty Liver Disease
This study is open to adults with overweight or obesity who also have fatty liver disease. The purpose of this study is to find the highest dose of BI 3006337 that people with overweight or obesity and with fatty liver disease…
- Trial name
- NCT05970640
- Testing
- BI 3006337
- Where
- 12 sites in United States
- Volunteers
- 64 people
- Sponsor
- Boehringer Ingelheim
Cardiovascular Diseases, Metabolic Syndrome
Redirecting Immune, Lipid and Metabolic Drivers of Early Cardiovascular Disease: The RESET Cohort Study
Project RESET is a Singapore National Medical Research Council Large Collaborative Grant funded program that brings together a nationwide community of cardiovascular, metabolic, and digital health researchers, as well as…
- Conditions
- Cardiovascular Diseases, Metabolic Syndrome, Non-Alcoholic Fatty Liver Disease
- Trial name
- RESET (NCT06211868)
- Testing
- Digital wearable and AI-human symbiotic lifestyle intervention
- Where
- Singapore
- Volunteers
- 3,000 people
- Sponsor
- National University Hospital, Singapore
Non-alcoholic Steatohepatitis, Liver Diseases
Reducing Non-Alcoholic Steatohepatitis
The goal of this clinical trial is to learn if empagliflozin works to treat non-alcoholic steatohepatitis in adults. The objectives are: Primary Objective To evaluate the change in histological grading and staging of NASH in…
- Conditions
- Non-alcoholic Steatohepatitis, Liver Diseases, Diabetes Mellitus, Type 2, Fibrosis, Liver
- Trial name
- RedNASH (NCT06519448)
- Testing
- Empagliflozin 10 miligrams (mg)
- Where
- Czechia
- Volunteers
- 30 people
- Sponsor
- Military University Hospital, Prague
MASLD, MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)
Accurate Point of Care Liver Disease Diagnostics (Phase 2)
This research study is being conducted to find out more about techniques to non-invasively evaluate liver disease. This is the second phase of a project in which we are testing a new technology to evaluate the liver…
- Conditions
- MASLD, MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease), NAFLD, NAFLD (Nonalcoholic Fatty Liver Disease)
- Trial name
- NCT07518784
- Testing
- LiverScope® exam, MR exam, Blood draw
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of California, San Diego
Chronic Liver Disease, Non-Alcoholic Fatty Liver Disease
Ultrasound Method to Measure Fibrosis of the Liver in Children
HYPOTHESIS: The investigators hypothesize that sonoelastography (SE) provide accurate quantitative measurements that can be used to stage liver fibrosis in pediatric patients with chronic liver disease.
- Conditions
- Chronic Liver Disease, Non-Alcoholic Fatty Liver Disease, HCV Coinfection, HBV
- Trial name
- NCT02086708
- Testing
- Shear Wave sonoelastography
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Massachusetts General Hospital
Non-Alcoholic Fatty Liver Disease
Measuring Fatty Liver With Ultrasound and MRS in Children With Overweight or Obesity
Obesity is associated with a variety of comorbidities, amongst which non-alcoholic fatty liver disease (NAFLD). A recent meta-analysis has shown that the prevalence of NAFLD in obese pediatric populations is around 35%, compared…
- Trial name
- NCT03787108
- Testing
- Magnetic resonance spectroscopy measurement
- Where
- Netherlands
- Volunteers
- 53 people
- Sponsor
- Maastricht University Medical Center
NAFLD
Non-alcoholic Fatty Liver Disease in Low Birth Weight Individuals
The investigators will conduct a proof-of-principle 4-weeks low-calorie diet (LCD) intervention study in low birth weight (LBW) subjects and normal birth weight (NBW) controls with documented (MR scan) liver fat content equal to…
- Trial name
- NCT05842850
- Testing
- Caloric restriction intervention, No intervention
- Where
- 2 sites in Denmark
- Volunteers
- 8 people
- Sponsor
- Steno Diabetes Center Copenhagen
Nonalcoholic Steatohepatitis
Safety and Efficacy Study of IMM 124-E (Bovine Colostrum) for Patients With Nonalcoholic Steatohepatitis
This is a multi-center, randomized, placebo-controlled, double-blind, dose-selection, multiple dose administration study comprising three groups, with up to 40 patients in each active treatment and placebo group.
- Trial name
- NCT01466894
- Testing
- IMM 124-E
- Sponsor
- Immuron Ltd.
Type 2 Diabetes, Fatty Liver, Nonalcoholic
The Effects of a Novel Lifestyle Intervention Program on Insulin Sensitivity in Type 2 Diabetes
Moderate weight reduction by a moderately hypocaloric very-low-fat diet resulted in normalization of fasting hyperglycemia and reversal of hepatic insulin resistance in patients with poorly controlled type 2 diabetes.
- Trial name
- CH_DDZ (NCT04509245)
- Testing
- Low-calorie diet supported by an app-guided digital education program, nutritional coaching calls via phone
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- German Diabetes Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.